Press Release Details

Cerus Corporation Appoints C. Raymond Larkin, Jr. to Board of Directors

December, 09 1999
Cerus Corporation (Nasdaq: CERS), a leading developer of systems to improve the safety of transfusion blood products through inactivation of viruses, bacteria and other pathogens, announced today the election of C. Raymond Larkin, Jr. to its Board of Directors, effective January 1, 2000.

Mr. Larkin is the former President and Chief Executive Officer of Nellcor Puritan Bennett, Inc., a medical instrumentation company that was acquired by Mallinckrodt, Incorporated in 1997 for $2.1 billion. Mr. Larkin joined Nellcor in 1983 and became CEO in 1987. During his tenure as CEO, revenue grew from $120 million to approximately $1 billion.

“Ray brings to our Board over twenty years of success in the medical device industry,” said B. J. Cassin, Chairman of the Cerus Board. "With his proven experience in bringing medical device products to market, as well as his strategic vision for building a market leader, Ray will make a great addition to the Cerus Board."

Mr. Larkin will replace Henry E. Stickney, who has resigned from the Board effective December 31, 1999. “We are very appreciative of the contributions that Henry Stickney has made, going back to the very early days of the company,” said Cerus President and Chief Executive Officer Stephen Isaacs. “He has provided invaluable guidance during his nine year tenure on the Board of Directors.”

Cerus Corporation is developing systems to inactivate pathogens in platelets, plasma and red blood cells intended for transfusion. In addition, Cerus is developing a system to treat source plasma used for fractionation into various plasma products. The company's platform technologies, which prevent viral, bacterial and other cellular replication, have potential applications in the health care field beyond pathogen inactivation in blood components. Cerus has collaboration agreements with Baxter Healthcare and the Consortium for Plasma Science.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including uncertainties regarding product development and other factors discussed in the company's 1998 Annual Report on Form 10-K.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600